Trial Outcomes & Findings for Improving Quitline Support Study (NCT NCT03538938)
NCT ID: NCT03538938
Last Updated: 2024-07-12
Results Overview
Participants will be coded as abstinent if they self-report no smoking for the past 7 days at the assessment endpoint (6 month follow-up) and provide a saliva sample for cotinine testing with a value of \<4 ng/ml. Participants will be considered not abstinent if they are lost to follow-up, report any smoking in the past 7 days, return a saliva sample with cotinine greater than or equal to 4 ng/ml, or fail to return a usable saliva sample.
Recruitment status
COMPLETED
Study phase
PHASE4
Target enrollment
1316 participants
Primary outcome timeframe
6-months
Results posted on
2024-07-12
Participant Flow
A total of 1316 of the target 1408 participants were recruited between June 2018 and January 2023
Participant milestones
| Measure |
1-Call, Patch, SmokefreeTXT, Financial Incentive
Participants received: 1 quitline counseling call, 2 weeks of nicotine patch, SmokefreeTXT information, and financial incentives for treatment engagement
|
1-Call, Patch, SmokefreeTXT, No Financial Incentive
Participants received: 1 quitline counseling call, 2 weeks of nicotine patch, SmokefreeTXT information, and no financial incentives for treatment engagement
|
1-Call, Patch, No SmokefreeTXT, Financial Incentive
Participants received: 1 quitline counseling call, 2 weeks of nicotine patch, no SmokefreeTXT information, and financial incentives for treatment
|
1-Call, Patch, No SmokefreeTXT, No Financial Incentive
Participants received: 1 quitline counseling call, 2 weeks of nicotine patch, no SmokefreeTXT information, and no financial incentives for treatment engagement
|
1-Call, Patch+Loz, SmokefreeTXT, Financial Incentive
Participants received: 1 quitline counseling call, 4 weeks of nicotine patch and nicotine lozenges, SmokefreeTXT information, and financial incentives for treatment engagement
|
1-Call, Patch+Loz, SmokefreeTXT, No Financial Incentive
Participants received: 1 quitline counseling call, 4 weeks of nicotine patch and nicotine lozenges, SmokefreeTXT information, and no financial incentives for treatment engagement
|
1-Call, Patch+Loz, No SmokefreeTXT, Financial Incentive
Participants received: 1 quitline counseling call, 4 weeks of nicotine patch and nicotine lozenges, no SmokefreeTXT information, and financial incentives for treatment engagement
|
1-Call, Patch+Loz, No SmokefreeTXT, No Financial Incentive
Participants received: 1 quitline counseling call, 4 weeks of nicotine patch and nicotine lozenges, no SmokefreeTXT information, and no financial incentives for treatment engagement
|
4-Call, Patch, SmokefreeTXT, Financial Incentive
Participants received: 4 quitline counseling calls, 2 weeks of nicotine patch, SmokefreeTXT information, and financial incentives for treatment engagement
|
4-Call, Patch, SmokefreeTXT, No Financial Incentive
Participants received: 4 quitline counseling calls, 2 weeks of nicotine patch, SmokefreeTXT information, and no financial incentives for treatment engagement
|
4-Call, Patch, No SmokefreeTXT, Financial Incentive
Participants received: 4 quitline counseling calls, 2 weeks of nicotine patch, no SmokefreeTXT information, and financial incentives for treatment engagement
|
4-Call, Patch, No SmokefreeTXT, No Financial Incentive
Participants received: 4 quitline counseling calls, 2 weeks of nicotine patch, no SmokefreeTXT information, and no financial incentives for treatment engagement
|
4-Call, Patch+Loz, SmokefreeTXT, Financial Incentive
Participants received: 4 quitline counseling calls, 4 weeks of nicotine patch and nicotine lozenge, SmokefreeTXT information, and financial incentives for treatment engagement
|
4-Call, Patch+Loz, SmokefreeTXT, No Financial Incentive
Participants received: 4 quitline counseling calls, 4 weeks of nicotine patch and nicotine lozenge, SmokefreeTXT information, and no financial incentives for treatment engagement
|
4-Call, Patch+Loz, No SmokefreeTXT, Financial Incentive
Participants received: 4 quitline counseling calls, 4 weeks of nicotine patch and nicotine lozenge, no SmokefreeTXT information, and financial incentives for treatment engagement
|
4-Call, Patch+Loz, No SmokefreeTXT,No Financial Incentive
Participants received: 4 quitline counseling calls, 4 weeks of nicotine patch and nicotine lozenge, no SmokefreeTXT information, and no financial incentives for treatment engagement
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
83
|
84
|
80
|
85
|
82
|
82
|
84
|
82
|
80
|
81
|
81
|
80
|
82
|
85
|
82
|
83
|
|
Overall Study
COMPLETED
|
79
|
78
|
73
|
82
|
82
|
81
|
81
|
80
|
74
|
79
|
79
|
78
|
78
|
84
|
80
|
78
|
|
Overall Study
NOT COMPLETED
|
4
|
6
|
7
|
3
|
0
|
1
|
3
|
2
|
6
|
2
|
2
|
2
|
4
|
1
|
2
|
5
|
Reasons for withdrawal
| Measure |
1-Call, Patch, SmokefreeTXT, Financial Incentive
Participants received: 1 quitline counseling call, 2 weeks of nicotine patch, SmokefreeTXT information, and financial incentives for treatment engagement
|
1-Call, Patch, SmokefreeTXT, No Financial Incentive
Participants received: 1 quitline counseling call, 2 weeks of nicotine patch, SmokefreeTXT information, and no financial incentives for treatment engagement
|
1-Call, Patch, No SmokefreeTXT, Financial Incentive
Participants received: 1 quitline counseling call, 2 weeks of nicotine patch, no SmokefreeTXT information, and financial incentives for treatment
|
1-Call, Patch, No SmokefreeTXT, No Financial Incentive
Participants received: 1 quitline counseling call, 2 weeks of nicotine patch, no SmokefreeTXT information, and no financial incentives for treatment engagement
|
1-Call, Patch+Loz, SmokefreeTXT, Financial Incentive
Participants received: 1 quitline counseling call, 4 weeks of nicotine patch and nicotine lozenges, SmokefreeTXT information, and financial incentives for treatment engagement
|
1-Call, Patch+Loz, SmokefreeTXT, No Financial Incentive
Participants received: 1 quitline counseling call, 4 weeks of nicotine patch and nicotine lozenges, SmokefreeTXT information, and no financial incentives for treatment engagement
|
1-Call, Patch+Loz, No SmokefreeTXT, Financial Incentive
Participants received: 1 quitline counseling call, 4 weeks of nicotine patch and nicotine lozenges, no SmokefreeTXT information, and financial incentives for treatment engagement
|
1-Call, Patch+Loz, No SmokefreeTXT, No Financial Incentive
Participants received: 1 quitline counseling call, 4 weeks of nicotine patch and nicotine lozenges, no SmokefreeTXT information, and no financial incentives for treatment engagement
|
4-Call, Patch, SmokefreeTXT, Financial Incentive
Participants received: 4 quitline counseling calls, 2 weeks of nicotine patch, SmokefreeTXT information, and financial incentives for treatment engagement
|
4-Call, Patch, SmokefreeTXT, No Financial Incentive
Participants received: 4 quitline counseling calls, 2 weeks of nicotine patch, SmokefreeTXT information, and no financial incentives for treatment engagement
|
4-Call, Patch, No SmokefreeTXT, Financial Incentive
Participants received: 4 quitline counseling calls, 2 weeks of nicotine patch, no SmokefreeTXT information, and financial incentives for treatment engagement
|
4-Call, Patch, No SmokefreeTXT, No Financial Incentive
Participants received: 4 quitline counseling calls, 2 weeks of nicotine patch, no SmokefreeTXT information, and no financial incentives for treatment engagement
|
4-Call, Patch+Loz, SmokefreeTXT, Financial Incentive
Participants received: 4 quitline counseling calls, 4 weeks of nicotine patch and nicotine lozenge, SmokefreeTXT information, and financial incentives for treatment engagement
|
4-Call, Patch+Loz, SmokefreeTXT, No Financial Incentive
Participants received: 4 quitline counseling calls, 4 weeks of nicotine patch and nicotine lozenge, SmokefreeTXT information, and no financial incentives for treatment engagement
|
4-Call, Patch+Loz, No SmokefreeTXT, Financial Incentive
Participants received: 4 quitline counseling calls, 4 weeks of nicotine patch and nicotine lozenge, no SmokefreeTXT information, and financial incentives for treatment engagement
|
4-Call, Patch+Loz, No SmokefreeTXT,No Financial Incentive
Participants received: 4 quitline counseling calls, 4 weeks of nicotine patch and nicotine lozenge, no SmokefreeTXT information, and no financial incentives for treatment engagement
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
Death
|
0
|
0
|
2
|
0
|
0
|
1
|
0
|
1
|
1
|
1
|
0
|
0
|
1
|
1
|
0
|
1
|
|
Overall Study
Withdrawal by Subject
|
4
|
6
|
5
|
3
|
0
|
0
|
3
|
1
|
5
|
1
|
2
|
1
|
3
|
0
|
2
|
4
|
|
Overall Study
Incarcerated
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
Baseline Characteristics
Gender was missing for 2 randomized participants
Baseline characteristics by cohort
| Measure |
1-Call, Patch, SmokefreeTXT, Financial Incentive
n=83 Participants
Participants received: 1 quitline counseling call, 2 weeks of nicotine patch, SmokefreeTXT information, and financial incentives for treatment engagement
|
1-Call, Patch, SmokefreeTXT, No Financial Incentive
n=84 Participants
Participants received: 1 quitline counseling call, 2 weeks of nicotine patch, SmokefreeTXT information, and no financial incentives for treatment engagement
|
1-Call, Patch, No SmokefreeTXT, Financial Incentive
n=80 Participants
Participants received: 1 quitline counseling call, 2 weeks of nicotine patch, no SmokefreeTXT information, and financial incentives for treatment
|
1-Call, Patch, No SmokefreeTXT, No Financial Incentive
n=85 Participants
Participants received: 1 quitline counseling call, 2 weeks of nicotine patch, no SmokefreeTXT information, and no financial incentives for treatment engagement
|
1-Call, Patch+Loz, SmokefreeTXT, Financial Incentive
n=82 Participants
Participants received: 1 quitline counseling call, 4 weeks of nicotine patch and nicotine lozenges, SmokefreeTXT information, and financial incentives for treatment engagement
|
1-Call, Patch+Loz, SmokefreeTXT, No Financial Incentive
n=82 Participants
Participants received: 1 quitline counseling call, 4 weeks of nicotine patch and nicotine lozenges, SmokefreeTXT information, and no financial incentives for treatment engagement
|
1-Call, Patch+Loz, No SmokefreeTXT, Financial Incentive
n=84 Participants
Participants received: 1 quitline counseling call, 4 weeks of nicotine patch and nicotine lozenges, no SmokefreeTXT information, and financial incentives for treatment engagement
|
1-Call, Patch+Loz, No SmokefreeTXT, No Financial Incentive
n=82 Participants
Participants received: 1 quitline counseling call, 4 weeks of nicotine patch and nicotine lozenges, no SmokefreeTXT information, and no financial incentives for treatment engagement
|
4-Call, Patch, SmokefreeTXT, Financial Incentive
n=80 Participants
Participants received: 4 quitline counseling calls, 2 weeks of nicotine patch, SmokefreeTXT information, and financial incentives for treatment engagement
|
4-Call, Patch, SmokefreeTXT, No Financial Incentive
n=81 Participants
Participants received: 4 quitline counseling calls, 2 weeks of nicotine patch, SmokefreeTXT information, and no financial incentives for treatment engagement
|
4-Call, Patch, No SmokefreeTXT, Financial Incentive
n=81 Participants
Participants received: 4 quitline counseling calls, 2 weeks of nicotine patch, no SmokefreeTXT information, and financial incentives for treatment engagement
|
4-Call, Patch, No SmokefreeTXT, No Financial Incentive
n=80 Participants
Participants received: 4 quitline counseling calls, 2 weeks of nicotine patch, no SmokefreeTXT information, and no financial incentives for treatment engagement
|
4-Call, Patch+Loz, SmokefreeTXT, Financial Incentive
n=82 Participants
Participants received: 4 quitline counseling calls, 4 weeks of nicotine patch and nicotine lozenge, SmokefreeTXT information, and financial incentives for treatment engagement
|
4-Call, Patch+Loz, SmokefreeTXT, No Financial Incentive
n=85 Participants
Participants received: 4 quitline counseling calls, 4 weeks of nicotine patch and nicotine lozenge, SmokefreeTXT information, and no financial incentives for treatment engagement
|
4-Call, Patch+Loz, No SmokefreeTXT, Financial Incentive
n=82 Participants
Participants received: 4 quitline counseling calls, 4 weeks of nicotine patch and nicotine lozenge, no SmokefreeTXT information, and financial incentives for treatment engagement
|
4-Call, Patch+Loz, No SmokefreeTXT,No Financial Incentive
n=83 Participants
Participants received: 4 quitline counseling calls, 4 weeks of nicotine patch and nicotine lozenge, no SmokefreeTXT information, and no financial incentives for treatment engagement
|
Total
n=1316 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Age, Continuous
|
51.24 years
STANDARD_DEVIATION 12.36 • n=83 Participants
|
52.82 years
STANDARD_DEVIATION 11.00 • n=84 Participants
|
55.04 years
STANDARD_DEVIATION 10.34 • n=80 Participants
|
52.55 years
STANDARD_DEVIATION 11.36 • n=85 Participants
|
53.43 years
STANDARD_DEVIATION 12.45 • n=82 Participants
|
51.15 years
STANDARD_DEVIATION 11.79 • n=82 Participants
|
53.73 years
STANDARD_DEVIATION 11.08 • n=84 Participants
|
54.12 years
STANDARD_DEVIATION 11.84 • n=82 Participants
|
52.11 years
STANDARD_DEVIATION 13.03 • n=80 Participants
|
51.78 years
STANDARD_DEVIATION 12.58 • n=81 Participants
|
53.49 years
STANDARD_DEVIATION 12.06 • n=81 Participants
|
54.25 years
STANDARD_DEVIATION 12.26 • n=80 Participants
|
52.80 years
STANDARD_DEVIATION 12.25 • n=82 Participants
|
54.41 years
STANDARD_DEVIATION 12.27 • n=85 Participants
|
53.40 years
STANDARD_DEVIATION 11.75 • n=82 Participants
|
53.81 years
STANDARD_DEVIATION 12.23 • n=83 Participants
|
53.13 years
STANDARD_DEVIATION 11.91 • n=1316 Participants
|
|
Sex: Female, Male
Female
|
46 Participants
n=83 Participants • Gender was missing for 2 randomized participants
|
51 Participants
n=84 Participants • Gender was missing for 2 randomized participants
|
47 Participants
n=80 Participants • Gender was missing for 2 randomized participants
|
47 Participants
n=85 Participants • Gender was missing for 2 randomized participants
|
48 Participants
n=82 Participants • Gender was missing for 2 randomized participants
|
48 Participants
n=81 Participants • Gender was missing for 2 randomized participants
|
48 Participants
n=84 Participants • Gender was missing for 2 randomized participants
|
48 Participants
n=82 Participants • Gender was missing for 2 randomized participants
|
49 Participants
n=80 Participants • Gender was missing for 2 randomized participants
|
45 Participants
n=81 Participants • Gender was missing for 2 randomized participants
|
46 Participants
n=81 Participants • Gender was missing for 2 randomized participants
|
45 Participants
n=80 Participants • Gender was missing for 2 randomized participants
|
49 Participants
n=82 Participants • Gender was missing for 2 randomized participants
|
49 Participants
n=85 Participants • Gender was missing for 2 randomized participants
|
48 Participants
n=81 Participants • Gender was missing for 2 randomized participants
|
47 Participants
n=83 Participants • Gender was missing for 2 randomized participants
|
761 Participants
n=1314 Participants • Gender was missing for 2 randomized participants
|
|
Sex: Female, Male
Male
|
37 Participants
n=83 Participants • Gender was missing for 2 randomized participants
|
33 Participants
n=84 Participants • Gender was missing for 2 randomized participants
|
33 Participants
n=80 Participants • Gender was missing for 2 randomized participants
|
38 Participants
n=85 Participants • Gender was missing for 2 randomized participants
|
34 Participants
n=82 Participants • Gender was missing for 2 randomized participants
|
33 Participants
n=81 Participants • Gender was missing for 2 randomized participants
|
36 Participants
n=84 Participants • Gender was missing for 2 randomized participants
|
34 Participants
n=82 Participants • Gender was missing for 2 randomized participants
|
31 Participants
n=80 Participants • Gender was missing for 2 randomized participants
|
36 Participants
n=81 Participants • Gender was missing for 2 randomized participants
|
35 Participants
n=81 Participants • Gender was missing for 2 randomized participants
|
35 Participants
n=80 Participants • Gender was missing for 2 randomized participants
|
33 Participants
n=82 Participants • Gender was missing for 2 randomized participants
|
36 Participants
n=85 Participants • Gender was missing for 2 randomized participants
|
33 Participants
n=81 Participants • Gender was missing for 2 randomized participants
|
36 Participants
n=83 Participants • Gender was missing for 2 randomized participants
|
553 Participants
n=1314 Participants • Gender was missing for 2 randomized participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
3 Participants
n=83 Participants
|
3 Participants
n=84 Participants
|
5 Participants
n=80 Participants
|
1 Participants
n=85 Participants
|
1 Participants
n=82 Participants
|
2 Participants
n=82 Participants
|
4 Participants
n=84 Participants
|
4 Participants
n=82 Participants
|
2 Participants
n=80 Participants
|
4 Participants
n=81 Participants
|
5 Participants
n=81 Participants
|
0 Participants
n=80 Participants
|
3 Participants
n=82 Participants
|
6 Participants
n=85 Participants
|
3 Participants
n=82 Participants
|
3 Participants
n=83 Participants
|
49 Participants
n=1316 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
80 Participants
n=83 Participants
|
81 Participants
n=84 Participants
|
75 Participants
n=80 Participants
|
84 Participants
n=85 Participants
|
81 Participants
n=82 Participants
|
79 Participants
n=82 Participants
|
80 Participants
n=84 Participants
|
77 Participants
n=82 Participants
|
78 Participants
n=80 Participants
|
73 Participants
n=81 Participants
|
75 Participants
n=81 Participants
|
80 Participants
n=80 Participants
|
79 Participants
n=82 Participants
|
79 Participants
n=85 Participants
|
78 Participants
n=82 Participants
|
80 Participants
n=83 Participants
|
1259 Participants
n=1316 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=83 Participants
|
0 Participants
n=84 Participants
|
0 Participants
n=80 Participants
|
0 Participants
n=85 Participants
|
0 Participants
n=82 Participants
|
1 Participants
n=82 Participants
|
0 Participants
n=84 Participants
|
1 Participants
n=82 Participants
|
0 Participants
n=80 Participants
|
4 Participants
n=81 Participants
|
1 Participants
n=81 Participants
|
0 Participants
n=80 Participants
|
0 Participants
n=82 Participants
|
0 Participants
n=85 Participants
|
1 Participants
n=82 Participants
|
0 Participants
n=83 Participants
|
8 Participants
n=1316 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=83 Participants
|
2 Participants
n=84 Participants
|
2 Participants
n=80 Participants
|
3 Participants
n=85 Participants
|
1 Participants
n=82 Participants
|
1 Participants
n=82 Participants
|
0 Participants
n=84 Participants
|
1 Participants
n=82 Participants
|
1 Participants
n=80 Participants
|
0 Participants
n=81 Participants
|
0 Participants
n=81 Participants
|
0 Participants
n=80 Participants
|
0 Participants
n=82 Participants
|
2 Participants
n=85 Participants
|
0 Participants
n=82 Participants
|
1 Participants
n=83 Participants
|
14 Participants
n=1316 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=83 Participants
|
1 Participants
n=84 Participants
|
0 Participants
n=80 Participants
|
0 Participants
n=85 Participants
|
0 Participants
n=82 Participants
|
0 Participants
n=82 Participants
|
0 Participants
n=84 Participants
|
0 Participants
n=82 Participants
|
0 Participants
n=80 Participants
|
0 Participants
n=81 Participants
|
0 Participants
n=81 Participants
|
0 Participants
n=80 Participants
|
0 Participants
n=82 Participants
|
1 Participants
n=85 Participants
|
1 Participants
n=82 Participants
|
0 Participants
n=83 Participants
|
3 Participants
n=1316 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
1 Participants
n=83 Participants
|
1 Participants
n=84 Participants
|
0 Participants
n=80 Participants
|
0 Participants
n=85 Participants
|
0 Participants
n=82 Participants
|
0 Participants
n=82 Participants
|
0 Participants
n=84 Participants
|
0 Participants
n=82 Participants
|
0 Participants
n=80 Participants
|
0 Participants
n=81 Participants
|
0 Participants
n=81 Participants
|
0 Participants
n=80 Participants
|
0 Participants
n=82 Participants
|
0 Participants
n=85 Participants
|
0 Participants
n=82 Participants
|
0 Participants
n=83 Participants
|
2 Participants
n=1316 Participants
|
|
Race (NIH/OMB)
Black or African American
|
22 Participants
n=83 Participants
|
20 Participants
n=84 Participants
|
19 Participants
n=80 Participants
|
23 Participants
n=85 Participants
|
22 Participants
n=82 Participants
|
18 Participants
n=82 Participants
|
25 Participants
n=84 Participants
|
21 Participants
n=82 Participants
|
22 Participants
n=80 Participants
|
22 Participants
n=81 Participants
|
22 Participants
n=81 Participants
|
25 Participants
n=80 Participants
|
22 Participants
n=82 Participants
|
22 Participants
n=85 Participants
|
24 Participants
n=82 Participants
|
20 Participants
n=83 Participants
|
349 Participants
n=1316 Participants
|
|
Race (NIH/OMB)
White
|
54 Participants
n=83 Participants
|
56 Participants
n=84 Participants
|
52 Participants
n=80 Participants
|
56 Participants
n=85 Participants
|
54 Participants
n=82 Participants
|
55 Participants
n=82 Participants
|
52 Participants
n=84 Participants
|
54 Participants
n=82 Participants
|
54 Participants
n=80 Participants
|
54 Participants
n=81 Participants
|
54 Participants
n=81 Participants
|
52 Participants
n=80 Participants
|
55 Participants
n=82 Participants
|
54 Participants
n=85 Participants
|
53 Participants
n=82 Participants
|
57 Participants
n=83 Participants
|
866 Participants
n=1316 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=83 Participants
|
0 Participants
n=84 Participants
|
1 Participants
n=80 Participants
|
0 Participants
n=85 Participants
|
0 Participants
n=82 Participants
|
1 Participants
n=82 Participants
|
1 Participants
n=84 Participants
|
0 Participants
n=82 Participants
|
0 Participants
n=80 Participants
|
1 Participants
n=81 Participants
|
0 Participants
n=81 Participants
|
1 Participants
n=80 Participants
|
0 Participants
n=82 Participants
|
0 Participants
n=85 Participants
|
1 Participants
n=82 Participants
|
0 Participants
n=83 Participants
|
6 Participants
n=1316 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
6 Participants
n=83 Participants
|
4 Participants
n=84 Participants
|
6 Participants
n=80 Participants
|
3 Participants
n=85 Participants
|
5 Participants
n=82 Participants
|
7 Participants
n=82 Participants
|
6 Participants
n=84 Participants
|
6 Participants
n=82 Participants
|
3 Participants
n=80 Participants
|
4 Participants
n=81 Participants
|
5 Participants
n=81 Participants
|
2 Participants
n=80 Participants
|
5 Participants
n=82 Participants
|
6 Participants
n=85 Participants
|
3 Participants
n=82 Participants
|
5 Participants
n=83 Participants
|
76 Participants
n=1316 Participants
|
|
Region of Enrollment
United States
|
83 participants
n=83 Participants
|
84 participants
n=84 Participants
|
80 participants
n=80 Participants
|
85 participants
n=85 Participants
|
82 participants
n=82 Participants
|
82 participants
n=82 Participants
|
84 participants
n=84 Participants
|
82 participants
n=82 Participants
|
80 participants
n=80 Participants
|
81 participants
n=81 Participants
|
81 participants
n=81 Participants
|
80 participants
n=80 Participants
|
82 participants
n=82 Participants
|
85 participants
n=85 Participants
|
82 participants
n=82 Participants
|
83 participants
n=83 Participants
|
1316 participants
n=1316 Participants
|
PRIMARY outcome
Timeframe: 6-monthsPopulation: All randomized participants were included in intent-to-treat analyses.
Participants will be coded as abstinent if they self-report no smoking for the past 7 days at the assessment endpoint (6 month follow-up) and provide a saliva sample for cotinine testing with a value of \<4 ng/ml. Participants will be considered not abstinent if they are lost to follow-up, report any smoking in the past 7 days, return a saliva sample with cotinine greater than or equal to 4 ng/ml, or fail to return a usable saliva sample.
Outcome measures
| Measure |
1-Call, Patch, SmokefreeTXT, Financial Incentive
n=83 Participants
Participants received: 1 quitline counseling call, 2 weeks of nicotine patch, SmokefreeTXT information, and financial incentives for treatment engagement
|
1-Call, Patch, SmokefreeTXT, No Financial Incentive
n=84 Participants
Participants received: 1 quitline counseling call, 2 weeks of nicotine patch, SmokefreeTXT information, and no financial incentives for treatment engagement
|
1-Call, Patch, No SmokefreeTXT, Financial Incentive
n=80 Participants
Participants received: 1 quitline counseling call, 2 weeks of nicotine patch, no SmokefreeTXT information, and financial incentives for treatment
|
1-Call, Patch, No SmokefreeTXT, No Financial Incentive
n=85 Participants
Participants received: 1 quitline counseling call, 2 weeks of nicotine patch, no SmokefreeTXT information, and no financial incentives for treatment engagement
|
1-Call, Patch+Loz, SmokefreeTXT, Financial Incentive
n=82 Participants
Participants received: 1 quitline counseling call, 4 weeks of nicotine patch and nicotine lozenges, SmokefreeTXT information, and financial incentives for treatment engagement
|
1-Call, Patch+Loz, SmokefreeTXT, No Financial Incentive
n=82 Participants
Participants received: 1 quitline counseling call, 4 weeks of nicotine patch and nicotine lozenges, SmokefreeTXT information, and no financial incentives for treatment engagement
|
1-Call, Patch+Loz, No SmokefreeTXT, Financial Incentive
n=84 Participants
Participants received: 1 quitline counseling call, 4 weeks of nicotine patch and nicotine lozenges, no SmokefreeTXT information, and financial incentives for treatment engagement
|
1-Call, Patch+Loz, No SmokefreeTXT, No Financial Incentive
n=82 Participants
Participants received: 1 quitline counseling call, 4 weeks of nicotine patch and nicotine lozenges, no SmokefreeTXT information, and no financial incentives for treatment engagement
|
4-Call, Patch, SmokefreeTXT, Financial Incentive
n=80 Participants
Participants received: 4 quitline counseling calls, 2 weeks of nicotine patch, SmokefreeTXT information, and financial incentives for treatment engagement
|
4-Call, Patch, SmokefreeTXT, No Financial Incentive
n=81 Participants
Participants received: 4 quitline counseling calls, 2 weeks of nicotine patch, SmokefreeTXT information, and no financial incentives for treatment engagement
|
4-Call, Patch, No SmokefreeTXT, Financial Incentive
n=81 Participants
Participants received: 4 quitline counseling calls, 2 weeks of nicotine patch, no SmokefreeTXT information, and financial incentives for treatment engagement
|
4-Call, Patch, No SmokefreeTXT, No Financial Incentive
n=80 Participants
Participants received: 4 quitline counseling calls, 2 weeks of nicotine patch, no SmokefreeTXT information, and no financial incentives for treatment engagement
|
4-Call, Patch+Loz, SmokefreeTXT, Financial Incentive
n=82 Participants
Participants received: 4 quitline counseling calls, 4 weeks of nicotine patch and nicotine lozenge, SmokefreeTXT information, and financial incentives for treatment engagement
|
4-Call, Patch+Loz, SmokefreeTXT, No Financial Incentive
n=85 Participants
Participants received: 4 quitline counseling calls, 4 weeks of nicotine patch and nicotine lozenge, SmokefreeTXT information, and no financial incentives for treatment engagement
|
4-Call, Patch+Loz, No SmokefreeTXT, Financial Incentive
n=82 Participants
Participants received: 4 quitline counseling calls, 4 weeks of nicotine patch and nicotine lozenge, no SmokefreeTXT information, and financial incentives for treatment engagement
|
4-Call, Patch+Loz, No SmokefreeTXT,No Financial Incentive
n=83 Participants
Participants received: 4 quitline counseling calls, 4 weeks of nicotine patch and nicotine lozenge, no SmokefreeTXT information, and no financial incentives for treatment engagement
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
7-Day Point-Prevalence Abstinence
|
11 Participants
|
7 Participants
|
8 Participants
|
10 Participants
|
6 Participants
|
10 Participants
|
10 Participants
|
15 Participants
|
4 Participants
|
16 Participants
|
10 Participants
|
7 Participants
|
12 Participants
|
8 Participants
|
16 Participants
|
12 Participants
|
Adverse Events
1-Call, Patch, SmokefreeTXT, Financial Incentive
Serious events: 7 serious events
Other events: 0 other events
Deaths: 0 deaths
1-Call, Patch, SmokefreeTXT, No Financial Incentive
Serious events: 5 serious events
Other events: 0 other events
Deaths: 0 deaths
1-Call, Patch, No SmokefreeTXT, Financial Incentive
Serious events: 11 serious events
Other events: 0 other events
Deaths: 2 deaths
1-Call, Patch, No SmokefreeTXT, No Financial Incentive
Serious events: 12 serious events
Other events: 0 other events
Deaths: 0 deaths
1-Call, Patch+Loz, SmokefreeTXT, Financial Incentive
Serious events: 11 serious events
Other events: 0 other events
Deaths: 0 deaths
1-Call, Patch+Loz, SmokefreeTXT, No Financial Incentive
Serious events: 4 serious events
Other events: 0 other events
Deaths: 1 deaths
1-Call, Patch+Loz, No SmokefreeTXT, Financial Incentive
Serious events: 10 serious events
Other events: 0 other events
Deaths: 0 deaths
1-Call, Patch+Loz, No SmokefreeTXT, No Financial Incentive
Serious events: 5 serious events
Other events: 0 other events
Deaths: 1 deaths
4-Call, Patch, SmokefreeTXT, Financial Incentive
Serious events: 6 serious events
Other events: 0 other events
Deaths: 1 deaths
4-Call, Patch, SmokefreeTXT, No Financial Incentive
Serious events: 12 serious events
Other events: 0 other events
Deaths: 1 deaths
4-Call, Patch, No SmokefreeTXT, Financial Incentive
Serious events: 12 serious events
Other events: 0 other events
Deaths: 0 deaths
4-Call, Patch, No SmokefreeTXT, No Financial Incentive
Serious events: 10 serious events
Other events: 0 other events
Deaths: 0 deaths
4-Call, Patch+Loz, SmokefreeTXT, Financial Incentive
Serious events: 5 serious events
Other events: 0 other events
Deaths: 1 deaths
4-Call, Patch+Loz, SmokefreeTXT, No Financial Incentive
Serious events: 10 serious events
Other events: 0 other events
Deaths: 1 deaths
4-Call, Patch+Loz, No SmokefreeTXT, Financial Incentive
Serious events: 7 serious events
Other events: 0 other events
Deaths: 0 deaths
4-Call, Patch+Loz, No SmokefreeTXT,No Financial Incentive
Serious events: 12 serious events
Other events: 0 other events
Deaths: 1 deaths
Serious adverse events
| Measure |
1-Call, Patch, SmokefreeTXT, Financial Incentive
n=83 participants at risk
Participants received: 1 quitline counseling call, 2 weeks of nicotine patch, SmokefreeTXT information, and financial incentives for treatment engagement
|
1-Call, Patch, SmokefreeTXT, No Financial Incentive
n=84 participants at risk
Participants received: 1 quitline counseling call, 2 weeks of nicotine patch, SmokefreeTXT information, and no financial incentives for treatment engagement
|
1-Call, Patch, No SmokefreeTXT, Financial Incentive
n=80 participants at risk
Participants received: 1 quitline counseling call, 2 weeks of nicotine patch, no SmokefreeTXT information, and financial incentives for treatment
|
1-Call, Patch, No SmokefreeTXT, No Financial Incentive
n=85 participants at risk
Participants received: 1 quitline counseling call, 2 weeks of nicotine patch, no SmokefreeTXT information, and no financial incentives for treatment engagement
|
1-Call, Patch+Loz, SmokefreeTXT, Financial Incentive
n=82 participants at risk
Participants received: 1 quitline counseling call, 4 weeks of nicotine patch and nicotine lozenges, SmokefreeTXT information, and financial incentives for treatment engagement
|
1-Call, Patch+Loz, SmokefreeTXT, No Financial Incentive
n=82 participants at risk
Participants received: 1 quitline counseling call, 4 weeks of nicotine patch and nicotine lozenges, SmokefreeTXT information, and no financial incentives for treatment engagement
|
1-Call, Patch+Loz, No SmokefreeTXT, Financial Incentive
n=84 participants at risk
Participants received: 1 quitline counseling call, 4 weeks of nicotine patch and nicotine lozenges, no SmokefreeTXT information, and financial incentives for treatment engagement
|
1-Call, Patch+Loz, No SmokefreeTXT, No Financial Incentive
n=82 participants at risk
Participants received: 1 quitline counseling call, 4 weeks of nicotine patch and nicotine lozenges, no SmokefreeTXT information, and no financial incentives for treatment engagement
|
4-Call, Patch, SmokefreeTXT, Financial Incentive
n=80 participants at risk
Participants received: 4 quitline counseling calls, 2 weeks of nicotine patch, SmokefreeTXT information, and financial incentives for treatment engagement
|
4-Call, Patch, SmokefreeTXT, No Financial Incentive
n=81 participants at risk
Participants received: 4 quitline counseling calls, 2 weeks of nicotine patch, SmokefreeTXT information, and no financial incentives for treatment engagement
|
4-Call, Patch, No SmokefreeTXT, Financial Incentive
n=81 participants at risk
Participants received: 4 quitline counseling calls, 2 weeks of nicotine patch, no SmokefreeTXT information, and financial incentives for treatment engagement
|
4-Call, Patch, No SmokefreeTXT, No Financial Incentive
n=80 participants at risk
Participants received: 4 quitline counseling calls, 2 weeks of nicotine patch, no SmokefreeTXT information, and no financial incentives for treatment engagement
|
4-Call, Patch+Loz, SmokefreeTXT, Financial Incentive
n=82 participants at risk
Participants received: 4 quitline counseling calls, 4 weeks of nicotine patch and nicotine lozenge, SmokefreeTXT information, and financial incentives for treatment engagement
|
4-Call, Patch+Loz, SmokefreeTXT, No Financial Incentive
n=85 participants at risk
Participants received: 4 quitline counseling calls, 4 weeks of nicotine patch and nicotine lozenge, SmokefreeTXT information, and no financial incentives for treatment engagement
|
4-Call, Patch+Loz, No SmokefreeTXT, Financial Incentive
n=82 participants at risk
Participants received: 4 quitline counseling calls, 4 weeks of nicotine patch and nicotine lozenge, no SmokefreeTXT information, and financial incentives for treatment engagement
|
4-Call, Patch+Loz, No SmokefreeTXT,No Financial Incentive
n=83 participants at risk
Participants received: 4 quitline counseling calls, 4 weeks of nicotine patch and nicotine lozenge, no SmokefreeTXT information, and no financial incentives for treatment engagement
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Infections and infestations
Infection prompting hospitalization
|
3.6%
3/83 • Number of events 3 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/84 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
3.8%
3/80 • Number of events 3 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/85 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
3.7%
3/82 • Number of events 3 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
2.4%
2/84 • Number of events 2 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/80 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/81 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
2.5%
2/81 • Number of events 2 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
2.5%
2/80 • Number of events 2 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
2.4%
2/82 • Number of events 2 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/85 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/83 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
|
Cardiac disorders
Cardiovascular diagnoses and events
|
0.00%
0/83 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/84 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
2.5%
2/80 • Number of events 2 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
3.5%
3/85 • Number of events 4 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
2.4%
2/82 • Number of events 2 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/84 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/80 • Number of events 2 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/81 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
3.7%
3/81 • Number of events 3 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
2.5%
2/80 • Number of events 2 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/82 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/85 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/82 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/83 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
|
Blood and lymphatic system disorders
Anemia or bleeding disorder
|
0.00%
0/83 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/84 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/80 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/85 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/84 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/80 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/81 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/81 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/80 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/85 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/82 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/83 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
|
Endocrine disorders
Diabetes complications, thyroid disorder
|
0.00%
0/83 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/84 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/80 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/85 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/84 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/80 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/81 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/81 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/80 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/85 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/83 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
|
Eye disorders
Double vision
|
0.00%
0/83 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/84 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/80 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/85 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/84 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/80 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/81 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/81 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/80 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/85 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/83 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
|
Gastrointestinal disorders
Gastrointestinal disease, pancreatitis, ulcer, or injury (e.g., hernia)
|
1.2%
1/83 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/84 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/80 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
2.4%
2/85 • Number of events 2 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
2.4%
2/82 • Number of events 2 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/84 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/80 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/81 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/81 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
3.8%
3/80 • Number of events 3 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
2.4%
2/85 • Number of events 2 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/82 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/83 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
|
Injury, poisoning and procedural complications
Injury or poisoning
|
1.2%
1/83 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/84 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
2.5%
2/80 • Number of events 2 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/85 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/82 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/82 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
2.4%
2/84 • Number of events 2 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/82 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/80 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/81 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/81 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/80 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/85 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/83 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Cancer, biopsy, polyp, or cyst
|
0.00%
0/83 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/84 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/80 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/85 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/84 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
2.4%
2/82 • Number of events 2 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
2.5%
2/80 • Number of events 2 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/81 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
2.5%
2/81 • Number of events 2 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/80 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/85 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/82 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
2.4%
2/83 • Number of events 2 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
|
Nervous system disorders
Stroke, seizure, aneurysm, or suspected multiple sclerosis relapse
|
1.2%
1/83 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/84 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/80 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/85 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/82 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/84 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/80 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/81 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
2.5%
2/81 • Number of events 2 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/80 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/85 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/83 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
|
Pregnancy, puerperium and perinatal conditions
Pregnancy, delivery
|
0.00%
0/83 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/84 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/80 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/85 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/84 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/80 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/81 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/81 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/80 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/85 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/83 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
|
Product Issues
Reaction to new psychiatric medication
|
0.00%
0/83 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/84 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/80 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/85 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/84 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/80 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/81 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/81 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/80 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/85 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/83 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
|
Psychiatric disorders
Suicidal ideation, bipolar, schizophrenia, anxiety, or alcohol use disorder symptoms
|
0.00%
0/83 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/84 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
2.5%
2/80 • Number of events 2 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/85 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
2.4%
2/82 • Number of events 2 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/82 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
2.4%
2/84 • Number of events 2 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/80 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/81 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/81 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/80 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/82 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
2.4%
2/85 • Number of events 2 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
2.4%
2/82 • Number of events 2 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/83 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
|
Renal and urinary disorders
Kidney disease, or kidney or bladder infection
|
1.2%
1/83 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/84 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/80 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/85 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/84 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/82 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/80 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/81 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/81 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/80 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/85 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/83 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
|
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease or need for supplemental oxygen
|
0.00%
0/83 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/84 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/80 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/85 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/84 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/82 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/80 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/81 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/81 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/80 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/85 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/82 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
2.4%
2/83 • Number of events 2 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
|
Surgical and medical procedures
Planned orthopedic, gastric, or hernia surgery
|
0.00%
0/83 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/84 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/80 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
2.4%
2/85 • Number of events 2 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/82 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/84 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/80 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/81 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
2.5%
2/81 • Number of events 2 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/80 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/85 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/83 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
|
General disorders
Unknown or other reason for hospitalization
|
0.00%
0/83 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/84 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/80 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
2.4%
2/85 • Number of events 2 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/82 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/84 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/80 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
2.5%
2/81 • Number of events 2 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/81 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/80 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/82 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
2.4%
2/85 • Number of events 2 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
0.00%
0/82 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
1.2%
1/83 • Number of events 1 • 6 months from target quit date (could be 7 months from study enrollment)
The study team assessed hospitalizations at 26-week follow-up as serious adverse assessments. Non-serious adverse events care were assessed by quitline coaches during quitline care and addressed according to standing quitline protocols.
|
Other adverse events
Adverse event data not reported
Additional Information
Danielle McCarthy
University of Wisconsin School of Medicine and Public Health
Phone: 6082655949
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place